Galecto, Inc.

Filter

År

Typ

Språk

2026-05-01 14:00:00 Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-30 14:00:00 Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-23 13:00:00 Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

2026-03-19 21:10:00 Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

2026-03-09 13:00:00 Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders

2026-03-04 14:00:00 Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-02-12 22:01:00 Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million 30,03 USD | +37,75%

2026-02-11 04:42:03 Galecto Announces Pricing of $275 Million Underwritten Public Offering 21,80 USD | +1,30%

2025-12-16 23:00:00 Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 30,00 USD | -5,06%

2025-11-10 13:00:00 Galecto Announces Acquisition of Damora Therapeutics 17,25 USD | +248,48%

2025-11-06 22:30:00 Galecto Reports Third Quarter 2025 Operating and Financial Results 5,82 USD | -2,02%

2025-08-05 22:15:00 Galecto Reports Second Quarter 2025 Operating and Financial Results 3,38 USD | -1,17%

2025-05-08 22:30:00 Galecto Reports First Quarter 2025 Operating and Financial Results 2,80 USD | +3,32%

2025-03-19 21:45:00 Galecto Reports Full-Year 2024 Financial Results 4,31 USD | +0,47%

2025-02-06 14:00:00 Galecto to Participate in Upcoming Investor Conferences 4,91 USD | -3,54%

2024-11-01 13:30:00 Galecto Reports Third Quarter 2024 Financial Results

2024-10-15 14:30:00 Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler 6,74 USD | -4,40%

2024-10-07 14:45:46 Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines 8,46 USD | -27,34%

2024-08-28 15:00:00 Galecto Announces Reverse Stock Split 0,52 USD | -6,58%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Språk